Randomized pharmacokinetic and pharmacodynamic comparison of fluoroquinolones for tuberculous meningitis

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 7, 2011, Pages 3244-3253

  Thwaites, Guy E ^a,b   Bhavnani, Sujata M ^c   Chau, Tran Thi Hong ^d   Hammel, Jeffrey P ^c   Török, M Estée ^e   Van Wart, Scott A ^c   Mai, Pham Phuong ^d   Reynolds, Daniel K ^c   Caws, Maxine ^b   Dung, Nguyen Thi ^d   Hien, Tran Tinh ^d   Kulawy, Robert ^c   Farrar, Jeremy ^b   Ambrose, Paul G ^c  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b OXFORD UNIVERSITY CLINICAL RESEARCH UNIT   (Viet Nam)

^c INSTITUTE FOR CLINICAL PHARMACODYNAMICS   (United States)

^d UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^e CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; ETHAMBUTOL; GATIFLOXACIN; ISONIAZID; LEVOFLOXACIN; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ADOLESCENT; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CEREBROSPINAL FLUID; CONTROLLED STUDY; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EXPOSURE; DRUG PENETRATION; DRUG SUBSTITUTION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PHARMACODYNAMICS; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT RESPONSE; TUBERCULOUS MENINGITIS;

EID: 79959226711     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00064-11     Document Type: Article

References (39)

1. Alffenaar, J. W., et al. 2008. Plasma and cerebrospinal fluid pharmacokinetics of moxifloxacin in a patient with tuberculous meningitis. Antimicrob. Agents Chemother. 52:2293-2295.
2. Alffenaar, J. W., et al. 2009. Pharmacokinetics of moxifloxacin in cerebrospinal fluid and plasma in patients with tuberculous meningitis. Clin. Infect. Dis. 49:1080-1082.
3. Barriere, S. L., G. W. Kaatz, and S. M. Seo. 1989. Enhanced elimination of ciprofloxacin after multiple-dose administration of rifampin to rabbits. Antimicrob. Agents Chemother. 33:589-590.
4. Barsić, B., et al. 1991. Entry of ciprofloxacin into cerebrospinal fluid during bacterial, viral and tuberculous meningitis. Neurol. Croat. 40:111-116.
5. Bayer HealthCare Pharmaceuticals, Inc. 2008. Cipro (ciprofloxacin) tablets and suspension package insert. Bayer HealthCare Pharmaceuticals, Inc., Wayne, NJ.
6. Beal, S., L. B. Sheiner, A. Boeckmann, and R. J. Bauer. 2009. NONMEM user's guides (1989-2009). Icon Development Solutions, Ellicott City, MD.
7. Berning, S. E., T. A. Cherry, and M. D. Iseman. 2001. Novel treatment of meningitis caused by multidrug-resistant Mycobacterium tuberculosis with intrathecal levofloxacin and amikacin: case report. Clin. Infect. Dis. 32:643-646.
8. Bristol-Myers Squibb Company. 2002. Tequin (gatifloxacin) tablets and injection package insert. Bristol-Myers Squibb Company, Princeton, NJ.
9. British Medical Research Council. 1948. Streptomycin treatment of tuberculous meningitis. Lancet i:582-596.
10. Chan, E. D., and M. D. Iseman. 2008. Multidrug-resistant and extensively drug-resistant tuberculosis: a review. Curr. Opin. Infect. Dis. 21:587-595.
11. Conde, M. B., et al. 2009. Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomized, controlled phase II trial. Lancet 373:1183-1189.
12. de Lange, E. C. 2004. Potential role of ABC transporters as a detoxification system at the blood-CSF barrier. Adv. Drug Deliv. Rev. 56:1793-1809.
13. DeVincenzo, J. P., S. E. Berning, C. A. Peloquin, and R. N. Husson. 1999. Multidrug-resistant tuberculosis meningitis: clinical problems and concentrations of second-line antituberculous medications. Ann. Pharmacother. 33:1184-1188.
14. Disratthakit, A., and N. Doi. 2010. In vitro activities of DC-159a, a novel fluoroquinolone, against Mycobacterium species. Antimicrob. Agents Chemother. 54:2684-2686.
15. Forrest, A., C. H. Ballow, D. E. Nix, M. C. Birmingham, and J. J. Schentag. 1993. Development of a population pharmacokinetic model and optimal sampling strategies for intravenous ciprofloxacin. Antimicrob. Agents Chemother. 37:1065-1072.
16. Fung-Tomc, J., et al. 2000. In vitro antibacterial spectrum of a new broadspectrum 8-methoxy fluoroquinolone, gatifloxacin. J. Antimicrob. Chemother. 45:437-446.
17. Gumbo, T., A. Louie, M. R. Deziel, and G. L. Drusano. 2005. Pharmacodynamic evidence that ciprofloxacin failure against tuberculosis is not due to poor microbial kill but to rapid emergence of resistance. Antimicrob. Agents Chemother. 49:3178-3181.
18. Hosmer, D. W., and S. Lemeshow. 1989. Applied logistic regression. Wiley, New York, NY.
19. Hosoglu, S., et al. 2002. Predictors of outcome in patients with tuberculous meningitis. Int. J. Tuberc. Lung Dis. 6:64-70.
20. Maeda, T., et al. 2007. Identification of influx transporter for the quinolone antibacterial agent levofloxacin. Mol. Pharm. 4:85-94.
21. Ogawa, M., H. Suzuki, Y. Sawada, M. Hanano, and Y. Sugiyama. 1994. Kinetics of active efflux via choroid plexus of beta-lactam antibiotics from the CSF into the circulation. Am. J. Physiol. 266:R392-R399.
22. Ooie, T., H. Suzuki, T. Terasaki, and Y. Sugiyama. 1996. Characterization of the transport properties of a quinolone antibiotic, fleroxacin, in rat choroid plexus. Pharm. Res. 13:523-527.
23. Ortho-McNeil-Janssen Pharmaceuticals, Inc. 2009. Levaquin (levofloxacin) tablets and injection package insert. Ortho-McNeil-Janssen Pharmaceuticals, Inc., Raritan, NJ.
24. Peloquin, C. A., et al. 2008. Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis. Antimicrob. Agents Chemother. 52:852-857.
25. Preston, S. L., et al. 1998. Levofloxacin population pharmacokinetics and creation of a demographic model for prediction of individual drug clearance in patients with serious community-acquired infection. Antimicrob. Agents Chemother. 42:1098-1104.
26. Rathore, M. S., and D. K. Majumdar. 2006. Effect of formulation factors on in vitro transcorneal permeation of gatifloxacin from aqueous drops. AAPS PharmSciTech 7:57.
27. Rodriguez, J. C., M. Ruiz, A. Climent, and G. Royo. 2001. In vitro activity of four fluoroquinolones against Mycobacterium tuberculosis. Int. J. Antimicrob. Agents 17:229-231.
28. Rodriguez, J. C., M. Ruiz, M. Lopez, and G. Royo. 2002. In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis. Int. J. Antimicrob. Agents 20:464-467.
29. Ruiz-Serrano, M. J., et al. 2000. In vitro activities of six fluoroquinolones against 250 clinical isolates of Mycobacterium tuberculosis susceptible or resistant to first-line antituberculosis drugs. Antimicrob. Agents Chemother. 44:2567-2568.
30. Singh, M., et al. 2009. In vitro effect of fluoroquinolones against Mycobacterium tuberculosis isolates from Agra & Kanpur region of north India. Indian J. Med. Res. 129:542-547.
31. Teasdale, G., and B. Jennett. 1974. Assessment of coma and impaired consciousness. A practical scale. Lancet ii:81-84.
32. Thwaites, G. E., et al. 2003. Pathophysiology and prognosis in Vietnamese adults with tuberculosis meningitis. J. Infect. Dis. 188:1105-1115.
33. Thwaites, G. E., et al. 2004. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. N. Engl. J. Med. 351:1741-1751.
34. Thwaites, G. E., et al. 2005. The influence of HIV infection on clinical presentation, response to treatment, and outcome in adults with tuberculous meningitis. J. Infect. Dis. 192:2134-2141.
35. Thwaites, G. E., and T. H. Tran. 2005. Tuberculous meningitis: many questions, too few answers. Lancet Neurol. 4:160-170.
36. Tsukamura, M., E. Nakamura, S. Yoshii, and H. Amano. 1985. Therapeutic effect of a new antibacterial substance ofloxacin (DL8280) on pulmonary tuberculosis. Am. Rev. Respir. Dis. 131:352-356.
37. Turnidge, J. 1999. Pharmacokinetics and pharmacodynamics of fluoroquinolones. Drugs 58(Suppl. 2):29-36. (Pubitemid 29500082)
38. Upton, A., A. Woodhouse, R. Vaughan, S. Newton, and R. Ellis-Pegler. 2009. Evolution of central nervous system multidrug-resistant Mycobacterium tuberculosis and late relapse of cryptic prosthetic hip joint tuberculosis: complications during treatment of disseminated isoniazid-resistant tuberculosis in an immunocompromised host. J. Clin. Microbiol. 47:507-510.
39. van Doorn, H. R., et al. 2008. Fluoroquinolone resistance detection in Mycobacterium tuberculosis with locked nucleic acid probe real-time PCR. Int. J. Tuberc. Lung Dis. 12:736-742.